HLA Class III Variant rs915654 Predicts Survival in Haploidentical Transplantation

Refining the Genetic Architecture of Haploidentical Transplantation

Allogeneic hematopoietic stem cell transplantation remains the primary curative intervention for high-risk hematologic malignancies, yet its success is frequently limited by the availability of human leukocyte antigen (HLA) matched donors [1, 2]. Haploidentical related donors have emerged as a vital alternative, offering outcomes comparable to matched unrelated donors while significantly expanding the donor pool [3, 4]. Despite advances in graft-versus-host disease prophylaxis and conditioning regimens, clinicians still face substantial challenges with post-transplant relapse and non-relapse mortality [5, 6]. Current donor selection algorithms primarily focus on HLA class I and II loci, but these markers do not fully account for the varied immune responses observed in clinical practice [7]. A new study now investigates how extending genetic analysis to include the HLA class III region, a segment of the major histocompatibility complex containing genes involved in the inflammatory response, may provide a more precise tool for predicting transplant success.

Identification of the rs915654 Genetic Marker

To investigate whether extended genetic profiles could improve clinical outcomes, the researchers evaluated the benefit of extended HLA class I, class III, and class II haplotypes (groups of genes inherited together from a single parent) in reducing mortality after hematopoietic-cell transplantation. The study focused on the HLA class III region, which is not typically typed in standard clinical practice despite its role in immune regulation. The discovery phase involved a large cohort of 1,436 patients and their haploidentical related donors, providing a robust dataset to examine how specific genetic variations influence post-transplant recovery and long-term survival. By expanding the search beyond traditional loci, the authors sought to identify hidden genetic drivers of transplant failure.

The researchers identified a robust class III single-nucleotide-polymorphism (SNP), designated as rs915654, which proved highly informative for predicting both mortality and relapse. A single-nucleotide-polymorphism is a variation at a single position in a DNA sequence among individuals, representing the most common type of genetic variation. This specific marker was isolated through a rigorous multivariable regression analysis of 26 candidate class III SNPs. By applying this statistical method to account for multiple variables simultaneously, the authors determined that rs915654 was a primary driver of clinical outcomes, independent of traditional HLA markers. This finding suggests that the inclusion of class III genetic data can refine the current understanding of the major histocompatibility complex and its role in transplant immunology, offering a more granular view of donor-recipient compatibility.

Predictive Modeling and Statistical Validation

To quantify the clinical impact of the identified genetic variation, the researchers constructed three-marker haplotypes, which are specific combinations of alleles located on the same chromosome that are typically inherited together. These three-marker haplotypes were defined by one class I locus, one class II locus, and the rs915654 single-nucleotide polymorphism. Crucially, the researchers determined these haplotypes in patients separately from donors, allowing for a granular analysis of how the genetic profile of each individual in the transplant pair contributes to the overall clinical outcome. This distinction is vital for clinicians when evaluating donor compatibility, as it suggests that the genetic risk profile is not merely a product of the donor-recipient match but also of the independent genetic architecture of each participant.

The statistical utility of adding rs915654 to existing prognostic frameworks was evaluated using the likelihood ratio test, a method used to compare the fit of two models to see if adding a specific variable significantly improves the prediction. When rs915654 was integrated into a relapse model containing patient HLA-E~DRB1, the model fit improved (likelihood ratio test P=0.06). A more pronounced improvement was observed when the SNP was added to a relapse model containing donor HLA-B~DRB1 (likelihood ratio test P=0.004). Similar trends were noted in mortality predictions. The inclusion of rs915654 into a mortality model containing patient HLA-E~DRB1 yielded an improvement (likelihood ratio test P=0.10), while its addition to a mortality model containing donor HLA-B~DRB1 resulted in a significant statistical gain (likelihood ratio test P=0.01). These data points indicate that the rs915654 variant provides independent prognostic information that complements traditional HLA markers, potentially allowing for more precise risk stratification in the haploidentical transplant setting.

Clinical Outcomes and Independent Cohort Verification

The clinical utility of these genetic markers is most evident when examining the cumulative effect of favorable alleles on patient survival and disease recurrence. The researchers observed a clear dose-response relationship where the risks of mortality and relapse increased with decreasing numbers of favorable patient and donor markers. This finding suggests that the prognostic value of the HLA class III region is additive, meaning that clinicians may eventually use a composite score of these markers to better estimate post-transplant outcomes. Beyond disease recurrence, the genetic profile also influenced complications unrelated to the primary malignancy; specifically, the number of unfavorable markers additionally increased non-relapse mortality, which includes deaths resulting from graft-versus-host disease, infection, or organ toxicity rather than the return of the underlying leukemia or lymphoma.

To ensure these associations were not limited to the initial study population, the researchers re-tested their findings in an independent cohort of 1,141 haploidentical transplants. This validation step is critical for clinical application, as it demonstrates that the genetic associations are reproducible across different patient populations and transplant centers. The re-testing in the independent cohort yielded results similar to the discovery cohort, confirming that the rs915654 variant and its associated haplotypes are robust predictors of transplant success. By establishing this consistency in a large, separate group of over one thousand patients, the study provides a statistical foundation for integrating HLA class III screening into the standard donor selection process, potentially allowing for the identification of donors who carry a lower genetic risk for both relapse and treatment-related mortality.

Implications for Donor Selection and Future Practice

The integration of class III genetic data into existing HLA matching protocols provides a more granular framework for assessing donor suitability. To translate these findings into a clinical tool, the researchers categorized HLA-A~C~B~DRB1~DQB1 haplotypes according to their expected numbers of favorable markers, creating a tiered system of genetic risk. By mapping these extended haplotypes (the specific combination of alleles inherited together on a single chromosome), the study explored the theoretical utility of these extended haplotypes for selecting donors who are most likely to facilitate a successful transplant. This approach moves beyond simple HLA matching at the major loci by accounting for the cumulative impact of multiple genetic variants across the entire major histocompatibility complex.

The clinical implications of this research suggest that extended HLA class I~class III~class II haplotypes influence the success of hematopoietic-cell transplantation by modulating the risks of both disease recurrence and treatment-related complications. For clinicians managing patients without a fully matched sibling or unrelated donor, this genetic information offers a method to differentiate between multiple potential haploidentical relatives. The study concludes that the knowledge of donor HLA haplotypes may optimize the selection of haploidentical donors for future patients, potentially reducing the incidence of non-relapse mortality and improving overall survival. Furthermore, these findings inform the broader biology of the major histocompatibility complex in both health and disease, suggesting that class III variation is a critical, yet previously underutilized, component of transplant immunology.

References

1. Mushtaq MU, Shahzad M, Tariq E, et al. Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis.. Frontiers in oncology. 2022. doi:10.3389/fonc.2022.1005042

2. Ahmed ABM, Elagab EA, Ahmed EAA, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Myeloid Leukemia: A Systematic Review. Cureus. 2025. doi:10.7759/cureus.92549

3. Arcuri LJ, Aguiar MTM, Ribeiro AAF, Pacheco AGF. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019. doi:10.1016/j.bbmt.2019.07.028

4. Wu R, Ma L. Haploidentical Hematopoietic Stem Cell Transplantation Versus Umbilical Cord Blood Transplantation in Hematologic Malignancies: A Systematic Review and Meta-Analysis. Cell Transplantation. 2020. doi:10.1177/0963689720964771

5. Gaballa S, Ge I, Fakih RE, et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.. Cancer. 2016. doi:10.1002/cncr.30180

6. Nguyen S, Chalandon Y, Lemarie C, et al. [Haploidentical hematopoietic stem cell transplantation: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)].. Bulletin du cancer. 2016. doi:10.1016/j.bulcan.2016.09.007

7. Zhang X, Chen J, Han M, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. Journal of Hematology & Oncology. 2021. doi:10.1186/s13045-021-01159-2